期刊文献+

MAPREC与MNVT评价Ⅲ型Sabin株脊髓灰质炎病毒神经毒力的比较

Evaluation of the neurovirulence of type Ⅲ Sabin strain poliovirus through MAPREC and MNVT
下载PDF
导出
摘要 目的用PCR扩增及限制性酶切分析突变技术(MAPREC)和猴体神经毒力试验(MNVT)评价同一批Ⅲ型Sabin株脊灰病毒神经毒力的结果差异。方法采用MAPREC技术,检测Ⅲ型Sabin株脊灰病毒神经毒力关键位点472位点突变率;采用MNVT病理切片分析,评价Ⅲ型Sabin株脊灰病毒神经毒力。结果 MAPREC检测待测样品核酸472位点突变率均值为0.324%,低于高突变参考品的0.621%。MNVT切片结果分析表明,xtest–xref=0.169,小于C1。对同一批样品,MAPREC与MNVT分析结果一致。结论在Ⅲ型Sabin株脊灰病毒神经毒力检测方面,操作简单,试验周期短的MAPREC技术可作为金标准MNVT的有益补充。 Objective To study the difference between the neurovirulence of the same type Ⅲ Sabin strain poliovirus examined by MAPREC and MNVT. Methods The MARPEC assay was used to detect the point mutation rate of the 472 site, which are the key sites of the virulence of the type Ⅲ Sabin strain poliovirus. The paraffin sections of the MNVT was analyzed to evaluate the neurovirulence of the type Ⅲ Sabin strain poliovirus. Results The average mutation rate of 472 site in MAPREC assay was 0.324%, which was lower than 0.621% of HMVR. The paraffin sections results of MNVT showed that xtest xref = 0.169, and the result was less than C1. The results of MAPREC of the same batch of samples were consistent with the results of MNVT. Conclusion In the detection of virulence of poliovirus type Ⅲ Sabin strain, the simple operation and short test period of MAPREC can be used as a beneficial supplement to the gold standard MNVT.
作者 李娜 丁玲 马萌 孙千一 王红燕 李拓 LI Na;DING Ling;MA Meng;SUN Qian-yi;WANG Hong-yan;LI Tuo(Department of Quality Control,Beijing Bio-Institute Biological Products Co.,Ltd.,Beijing 100176,China;Department of Vaccine Facility 4,Beijing Bio-Institute Biological Products Co.,Ltd.,Beijing 100176,China)
出处 《中国医药生物技术》 2019年第6期494-499,共6页 Chinese Medicinal Biotechnology
基金 “重大新药创制”国家科技重大专项(2018ZX09737008)
关键词 神经毒力 Ⅲ型Sabin株脊髓灰质炎病毒 分子水平 动物水平 Neurovirulence Type Ⅲ Sabin strain poliovirus Molecular level Animal level
  • 相关文献

参考文献4

二级参考文献48

  • 1梁晓峰,童亦兵,冯子健,徐爱强,张丽,张大勇,雷杰,于竞进.中国首次疫苗衍生脊髓灰质炎病毒循环事件的发现及处理[J].中国计划免疫,2005,11(4):245-247. 被引量:56
  • 2温宁,左树岩,殷大鹏,夏伟,邹建,喻浩.中国疫苗衍生脊髓灰质炎病毒循环事件的流行病学调查[J].中国计划免疫,2005,11(4):248-251. 被引量:23
  • 3卫生部.2004年全国计划免疫审评报告[M].北京:人民卫生出版社,2005.
  • 4陈淑范 罗国祥 叶正中 等.27年来我所生产的脊髓灰质炎减毒活疫苗猴体神经毒力试验结果的分析[J].医学生物学研究,1988,3:1-7.
  • 5罗其胜 罗国祥 陈淑范 等.口服脊髓灰质炎减毒活疫苗猴体神经毒力试验病理结果检定分析[J].医学生物学研究,1989,2:8-14.
  • 6Wright PF, Kim-Farley R J, de Quadros CA, et al. Strategies for the global eradication of poliomyelitis by the year 2000 [ J ]. The New England journal of medicine, 1991, 325 (25) : 1774-1779.
  • 7WHO EPI. Poliomyelitis in 1987, 1988, and 1989-Part I [ J]. WER, 1991, 66(8) :49-54.
  • 8Polio Global Eradication Initiative. Looking back on 2012 [ EB/ OL]. Available at http://www, polioeradication, org/Mediaroom/ Newsstories/Newsstories2013/tabid/488/iid/267/Defauh. aspx. Jan. 13, 2013.
  • 9Polio Global Eradication Initiative. Polio Eradication and Endgame Strategic Plan 2013-2018 [ EB/OL ]. Aailable at http://www. polioeradieation, org/Portals/0/Doeument/Resourees/Strategy Work /PEESP_ES EN A4. pdf. May 8, 2013.
  • 10Stanley A Plotkin, Waher A Orenstein, Paul A Offit. Vaccine [ M ]. Fifth Edition, Elsevier (Singapore) Pte Ltd., 2008 : 605- 686.

共引文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部